



## **RegenesiS Biomedical Appoints Clinical Research Director**

*Building the body of clinical evidence for the Provant Therapy System*

Scottsdale, Arizona, January 23, 2012 -- RegenesiS Biomedical, Inc., a medical technology company that markets the Provant<sup>®</sup> Therapy System, announced today Gregory Shipp, MD, joined the company as Director of Clinical Research. In this new role, Dr. Shipp will execute the company's clinical trial strategy. Clinical and outcomes data will strengthen RegenesiS' regulatory, reimbursement, and commercial positions.

Prior to joining RegenesiS, Dr. Shipp held clinical affairs positions at Boston Scientific, Abbott, Physio-Control, and Nanosphere. His responsibilities have included clinical trial design, post-market surveillance, defining regulatory strategies, and supporting FDA clearances. Areas of research have included ophthalmology, plastic surgery, urology, bone physiology, and laboratory chemistry.

"Greg's healthcare industry experience matches key elements of our strategic plan," said Richard Isenberg, MD, Vice President of Regulatory and Clinical Affairs of RegenesiS. "Further demonstrating the clinical and health economics value of Provant will increase access to patients in need."

Dr. Shipp earned his bachelor and master degrees in biomedical engineering from Northwestern University, and his medical doctorate from the University of North Carolina, Chapel Hill.

### About RegenesiS Biomedical

RegenesiS Biomedical, Inc. is a privately held medical technology company focused on developing and marketing noninvasive regenerative medicine products. RegenesiS developed, patented, and now markets the Provant Therapy System. Our customers include health care facilities, acute care hospitals, long-term acute care hospitals, skilled nursing facilities, rehabilitation centers, home health care agencies, and wound care clinics.

### About the Provant<sup>®</sup> Therapy System

Provant uses pulsed radio frequency energy (PRFE) to facilitate reduction of the pain and edema associated with post-operative, superficial soft tissues.

Contact: RegenesiS Biomedical, Inc.  
Scott Robey, Vice President Marketing  
[www.regenesibio.com](http://www.regenesibio.com)  
480-970-4970 phone

SOURCE: RegenesiS Biomedical Inc.